Recently released clinical practice guidelines (CPGs) no longer recommend decision thresholds of prostate-specific antigen (PSA) for the early detection of prostate cancer (PCa) to rule in patients for prostate biopsy referral [1,2,3]. The gene discussed is KLK3; the disease is posterior cortical atrophy.